Business Wire

CA-NETAPP,-INC.

10.7.2024 14:01:33 CEST | Business Wire | Press release

Share
NetApp Expands Intelligent Data Infrastructure Capabilities to Power Strategic Cloud Workloads

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the introduction of new capabilities designed for strategic cloud workloads including GenAI and VMware. These enhancements to NetApp data and storage services reduce the resources and risks for customers to manage these strategic workloads across increasingly complex hybrid multicloud environments.

“Strategic workloads, including GenAI and virtualized environments, are driving business innovation and have increasingly complex and resource-intensive infrastructure requirements that are pushing IT teams to the limit,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “NetApp is helping customers take back control of their data with intelligent data infrastructure that leverages unified data storage, integrated data services, and automated cloud operations. Even when they are up against specific and nuanced technology requirements for modern workloads, NetApp gives them the tools they need to optimize and simplify their data operations in their environments across the hybrid multicloud.”

To advance intelligent data infrastructure deployments that better support strategic workloads like GenAI and VMware environments, NetApp is announcing new capabilities, including:

  • NetApp BlueXP Workload Factory – for AWS: This intelligent data infrastructure service uses defined industry best-practices to automate the planning, provisioning, and management of cloud resources and services for key workloads, including GenAI, VMware cloud environments, and enterprise databases. Customers can use BlueXP workload factory to optimize deployment time, cost, performance, and protection of resources for strategic workloads as well as their associated data. To simplify workload migrations to the cloud, BlueXP workload factory allows users to profile infrastructure requirements for target workloads and compare different resource options for cost and performance needs. Then, the service can provision the selected resources, move any existing workload data to these newly provisioned cloud deployments, and continually optimize the entire environment to ensure the required cost and performance targets. AWS users can read guidance on how to deploy this capability on the AWS Solutions Library.
  • NetApp GenAI Toolkit – Microsoft Azure NetApp Files Version: Customers can now include private enterprise data stored in Azure NetApp Files in their retrieval-augmented generation (RAG) workflows in a secure, programmatic manner. The result is an enhanced ability to generate unique, high-quality, and ultra-relevant results from GenAI projects by combining their proprietary data with pre-trained, foundational models (FMs). The integration of the NetApp GenAI Toolkit with Azure NetApp Files represents a powerful synergy that empowers customers to harness advanced language generation capabilities.
  • Amazon Bedrock with Amazon FSx for NetApp ONTAP Reference Architecture: Amazon Web Services, Inc. (AWS) and NetApp have released a joint reference architecture which provides guidance for customers on implementing RAG-enabled workflows that bring proprietary data stored on Amazon FSx for NetApp ONTAP into their GenAI data pipelines. Amazon FSx makes it easy and cost effective to launch, run, and scale feature-rich, high-performance file systems in the cloud. The reference architecture allows developers to use APIs for Amazon Bedrock to connect with Amazon FSx for ONTAP data stores, enabling the secure use of proprietary data with a choice of high-performing FMs that can be customized to unlock new insights and capabilities.
  • Amazon FSx for NetApp ONTAP Enhancements: AWS announced the next-generation Amazon FSx for ONTAP cloud storage service with enhanced capabilities to boost scalability and flexibility to provide up to 6 GB per second of throughput for a single highly-available (HA) pair from 512 TiB of SSD storage. Next-gen file systems offer virtualized workloads more room to grow with a 300 percent increase in network burst throughput and a 150 percent boost in disk burst throughput. For large-scale, high-performance workloads like GenAI, second-generation Amazon FSx for ONTAP systems support dynamic scalability by adding HA pairs as needed, up to 24 nodes. This delivers up to 72 GB per second of throughput from 1 PiB of SSD storage, providing greater flexibility and performance for evolving business needs.
  • NetApp BlueXP Disaster Recovery Support for VMFS: The BlueXP disaster recovery service, which provides guided workflows to design and execute automated disaster recovery plans for VMware workloads across both on-premises and cloud environments, has been expanded to support VMFS datastores for on-premises to on-premises disaster recovery.

These updates build on NetApp’s existing offerings that support storage and data operations for customers that need to implement and manage high-powered, strategic workloads such as GenAI and VMware environments. For example, NetApp recently announced that its unique BlueXP data classification capability, which automatically classifies and categorizes data for enhanced governance and secure ingest into GenAI and RAG data pipelines, has become a core control plane capability now available free of charge to all NetApp customers.

“When it comes to GenAI, the prime focus for organizations is to adapt their data strategies to ensure they can balance data security, cost efficiency and innovation as they leverage pre-built LLMs to surface relevant, useful insights from their proprietary, business-relevant data,” said Archana Venkatraman, Senior Research Director, Cloud Data Management at IDC. “NetApp’s intelligent data infrastructure capabilities can help customers overcome the data challenges and offer specific guidance to automate workflows that can securely feed private data directly into public cloud providers’ LLMs. In addition, NetApp’s BlueXP data classification capability has the potential to mitigate the risks in data operations for AI because it allows users to discover and categorize data so that the right data is fed into the right model without exposing confidential, personal or restricted information.”

“Organizations are now facing different economic realities with regards to virtualized environments, and we all need to move quickly to address recent industry shifts,” said Derek Elbert, Solutions Architect at WWT. “Optimizing the cost versus performance equation of VMware workloads has become a primary initiative for us, with the objective of continuing to provide scalability and performance while reducing unnecessary system and software resources. NetApp’s offerings, such as the BlueXP disaster recovery service and the optimization metrics from Cloud Insights, help us better ensure the right levels of resource allocation and protection schemes for virtual environments, allowing us to focus on putting our infrastructure to work without killing the FinOps metrics.”

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710415938/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye